Bruce A C Cree,, Mas

List of Publications by Year
in descending order

199 papers	22,886 citations	13865 67 h-index	8866 145 g-index
210 all docs	210 docs citations	210 times ranked	21421 citing authors

#	Article	IF	Citations
1	Polygenic risk score association with multiple sclerosis susceptibility and phenotype in Europeans. Brain, 2023, 146, 645-656.	7.6	15
2	Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. Multiple Sclerosis Journal, 2022, 28, 429-440.	3.0	40
3	Identifying falls remotely in people with multiple sclerosis. Journal of Neurology, 2022, 269, 1889-1898.	3.6	5
4	Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study. Multiple Sclerosis and Related Disorders, 2022, 57, 103352.	2.0	19
5	AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2022, 57, 103356.	2.0	16
6	Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis. Annals of Neurology, 2022, 91, 268-281.	5.3	39
7	Multiple sclerosis: two decades of progress. Lancet Neurology, The, 2022, 21, 211-214.	10.2	16
8	COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab. Neurology and Therapy, 2022, 11, 741-758.	3.2	18
9	Reply to â€œSpinal Cord Atrophy Is a Preclinical Marker of Progressive <scp>MS</scp>â€• Annals of Neurology, 2022, 91, 735-736.	5.3	0
10	Cryptococcal Meningitis Reported With Fingolimod Treatment. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	11
11	Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial. Multiple Sclerosis Journal, 2022, 28, 1526-1540.	3.0	16
12	Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5â€‰years. Multiple Sclerosis Journal, 2022, 28, 1591-1605.	3.0	19
13	A hormonal therapy for menopausal women with MS: A phase Ib/IIa randomized controlled trial. Multiple Sclerosis and Related Disorders, 2022, 61, 103747.	2.0	5
14	Challenges to Longitudinal Characterization of Lower Urinary Tract Dysfunction in Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2022, 62, 103793.	2.0	3
15	Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. Journal of Neurology, 2022, 269, 5093-5104.	3.6	7
16	The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis. CNS Drugs, 2022, 36, 703-719.	5.9	18
17	Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5â€‰years of follow-up in the DAYBREAK open-label extension trial. Multiple Sclerosis Journal, 2022, 28, 1944-1962.	3.0	16
18	Letter to the Editor Regarding â€œNetwork Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 ImmunoglobulinÂG-positive Neuromyelitis Optica Spectrum Disorderâ€• Neurology and Therapy, 2022, 11, 1439-1443.	3.2	4

#	Article	IF	Citations
19	An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1432-1441.	3.0	9
20	Household paired design reduces variance and increases power in multi-city gut microbiome study in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 366-379.	3.0	24
21	Retinal <scp>INL</scp> Thickness in Multiple Sclerosis: A Mere Marker of Neurodegeneration?. Annals of Neurology, 2021, 89, 192-193.	5.3	14
22	Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. Multiple Sclerosis and Related Disorders, 2021, 48, 102673.	2.0	20
23	Effects of COVID-19 â€œSheltering in Placeâ€•on Activity in People With Multiple Sclerosis. Neurology: Clinical Practice, 2021, 11, e216-e218.	1.6	8
24	Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 2021, 78, 48.	9.0	11
25	Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. Multiple Sclerosis Journal, 2021, 27, 2052-2061.	3.0	11
26	Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	20
27	Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 2219-2231.	3.0	7
28	Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. Annals of Neurology, 2021, 89, 895-910.	5.3	72
29	Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. Multiple Sclerosis and Related Disorders, 2021, 49, 102695.	2.0	5
30	Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. Multiple Sclerosis and Related Disorders, 2021, 51, 102844.	2.0	19
31	Secondary Progressive Multiple Sclerosis. Neurology, 2021, 97, 378-388.	1.1	100
32	Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders, 2021, 52, 103010.	2.0	13
33	Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials. European Journal of Neurology, 2021, 28, 3722-3730.	3.3	12
34	Detection of Neoplasms by Metagenomic Next-Generation Sequencing of Cerebrospinal Fluid. JAMA Neurology, 2021, 78, 1355.	9.0	14
35	Cell type-specific transcriptomics identifies neddylation as a novel therapeutic target in multiple sclerosis. Brain, 2021, 144, 450-461.	7.6	16
36	Siponimod and Cognition in Secondary Progressive Multiple Sclerosis. Neurology, 2021, 96, e376-e386.	1.1	64

#	Article	IF	Citations
37	Specific hypomethylation programs underpin B cell activation in early multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	14
38	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2020, 19, 988-997.	10.2	64
39	Treatment of Multiple Sclerosis: A Review. American Journal of Medicine, 2020, 133, 1380-1390.e2.	1.5	374
40	Gut microbiotaâ€“specific IgA ⁺ B cells traffic to the CNS in active multiple sclerosis. Science Immunology, 2020, 5, .	11.9	132
41	Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	22
42	Imaging correlates of visual function in multiple sclerosis. PLoS ONE, 2020, 15, e0235615.	2.5	5
43	A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22932-22943.	7.1	119
44	Neurite Orientation Dispersion and Density Imaging for Assessing Acute Inflammation and Lesion Evolution in MS. American Journal of Neuroradiology, 2020, 41, 2219-2226.	2.4	14
45	Switching to fingolimod in PREFERMS: Effect of treatment history and naÃ¯vety on clinical, MRI and treatment satisfaction outcomesâœ°. Multiple Sclerosis and Related Disorders, 2020, 45, 102346.	2.0	1
46	A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. Neurology, 2020, 95, e1027-e1040.	1.1	28
47	Imaging correlates of visual function in multiple sclerosis. , 2020, 15, e0235615.		0
48	Imaging correlates of visual function in multiple sclerosis. , 2020, 15, e0235615.		0
49	Imaging correlates of visual function in multiple sclerosis. , 2020, 15, e0235615.		0
50	Imaging correlates of visual function in multiple sclerosis. , 2020, 15, e0235615.		0
51	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. Multiple Sclerosis Journal, 2019, 25, 1255-1262.	3.0	37
52	Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1526-1534.	3.0	49
53	Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. JAMA Neurology, 2019, 76, 1359.	9.0	129
54	Reply to â€œSilent Progression or Bout Onset Progressive Multiple Sclerosis?â€• Annals of Neurology, 2019, 86, 472-473.	5.3	2

#	Article	IF	Citations
55	Telomere Length Is Associated with Disability Progression in Multiple Sclerosis. Annals of Neurology, 2019, 86, 671-682.	5.3	41
56	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet, The, 2019, 394, 1352-1363.	13.7	433
57	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurology, The, 2019, 18, 1009-1020.	10.2	191
58	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurology, The, 2019, 18, 1021-1033.	10.2	184
59	Lymphocyte counts and infection rates. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	6.0	7
60	Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science, 2019, 365, .	12.6	710
61	pRNFL as a marker of disability worsening in the medium/long term in patients with MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e533.	6.0	18
62	Author response: Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology, 2019, 92, 151.2-151.	1.1	0
63	A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis. Nature Communications, 2019, 10, 2236.	12.8	65
64	Association of Continuous Assessment of Step Count by Remote Monitoring With Disability Progression Among Adults With Multiple Sclerosis. JAMA Network Open, 2019, 2, e190570.	5.9	69
65	Silent progression in disease activityâ€“free relapsing multiple sclerosis. Annals of Neurology, 2019, 85, 653-666.	5.3	265
66	Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology, 2019, 266, 1182-1193.	3.6	61
67	Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. Current Opinion in Neurology, 2019, 32, 365-377.	3.6	73
68	Disease-modifying therapies alter gut microbial composition in MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e517.	6.0	75
69	The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimod. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731881924.	1.0	3
70	Rituximab in neurological disease: principles, evidence and practice. Practical Neurology, 2019, 19, 5-20.	1.1	59
71	Harnessing electronic medical records to advance research on multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 408-418.	3.0	21
72	Longitudinally persistent cerebrospinal fluid B-cells can resist treatment in multiple sclerosis. JCI Insight, 2019, 4, .	5.0	22

#	Article	IF	Citations
73	Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis â€“ Commentary. Multiple Sclerosis Journal, 2018, 24, 1161-1162.	3.0	5
74	Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology, 2018, 90, 789-800.	1.1	107
75	Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology, 2018, 90, 777-788.	1.1	406
76	Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology, 2018, 90, e1815-e1821.	1.1	123
77	Ovarian aging is associated with gray matter volume and disability in women with MS. Neurology, 2018, 90, e254-e260.	1.1	41
78	The Gut Microbiome in Neuromyelitis Optica. Neurotherapeutics, 2018, 15, 92-101.	4.4	54
79	Clemastine rescues myelination defects and promotes functional recovery in hypoxic brain injury. Brain, 2018, 141, 85-98.	7.6	83
80	Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the <scp>INFORMS</scp> study. Annals of Clinical and Translational Neurology, 2018, 5, 346-356.	3.7	17
81	Rituximab before and during pregnancy. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e453.	6.0	159
82	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273.	13.7	684
83	SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. Multiple Sclerosis Journal, 2018, 24, 1485-1498.	3.0	19
84	Longer-term Safety with Siponimod Treatment in Multiple Sclerosis: Pooled Analysis of Data from the Bold and Expand Trials and their Extensions. Multiple Sclerosis and Related Disorders, 2018, 26, 255-256.	2.0	0
85	Multiple Sclerosis-Associated Changes in the Composition and Immune Functions of Spore-Forming Bacteria. MSystems, 2018, 3, .	3.8	56
86	Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641877433.	3.5	22
87	Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study. Multiple Sclerosis and Related Disorders, 2018, 25, 50-56.	2.0	9
88	Multiple Sclerosis Therapy: Are We Ready for a One-Size-Fits-All Approach?. Journal of Neuro-Ophthalmology, 2018, 38, 258-262.	0.8	0
89	Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis. Annals of Neurology, 2018, 84, 51-63.	5.3	38
90	Multiple Sclerosis Genetics. , 2018, , .		0

#	Article	IF	Citations
91	Continuous daily assessment of multiple sclerosis disability using remote step count monitoring. Journal of Neurology, 2017, 264, 316-326.	3.6	109
92	Acute liver injury in a Glatopa-treated patient with MS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e368.	6.0	4
93	Onset of secondary progressive <scp>MS</scp> after longâ€term rituximab therapy â€“ a case report. Annals of Clinical and Translational Neurology, 2017, 4, 46-52.	3.7	22
94	Cerebral Gray Matter Atrophy Is Associated with the CSF IgG index in African American with Multiple Sclerosis. Journal of Neuroimaging, 2017, 27, 476-480.	2.0	17
95	Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet, The, 2017, 390, 2481-2489.	13.7	377
96	Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology, 2017, 89, 1584-1593.	1.1	65
97	Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10713-10718.	7.1	709
98	Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis. Neurotherapeutics, 2017, 14, 835-841.	4.4	141
99	Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients. JCI Insight, 2017, 2, .	5.0	84
100	Remote Physical Activity Monitoring in Neurological Disease: A Systematic Review. PLoS ONE, 2016, 11, e0154335.	2.5	156
101	Steering through complexity. Current Opinion in Neurology, 2016, 29, 263-271.	3.6	11
102	Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 4777-4782.	7.1	238
103	Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e272.	6.0	31
104	Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies. Neurology: Genetics, 2016, 2, e87.	1.9	76
105	Longâ€term evolution of multiple sclerosis disability in the treatment era. Annals of Neurology, 2016, 80, 499-510.	5.3	331
106	Gut microbiome analysis in neuromyelitis optica reveals overabundance of Clostridium perfringens. Annals of Neurology, 2016, 80, 443-447.	5.3	125
107	Association of HLA Genetic Risk Burden With Disease Phenotypes in Multiple Sclerosis. JAMA Neurology, 2016, 73, 795.	9.0	64
108	Placebo-controlled study in neuromyelitis opticaâ€"Ethical and design considerations. Multiple Sclerosis Journal, 2016, 22, 862-872.	3.0	63

#	Article	IF	Citations
109	Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet, The, 2016, 387, 1075-1084.	13.7	379
110	Characterizing retinal structure injury in African-Americans with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 7, 16-20.	2.0	12
111	Statistical Considerations for an Adaptive Design for a Serious Rare Disease. Therapeutic Innovation and Regulatory Science, 2016, 50, 375-384.	1.6	3
112	Inclusion of brain volume loss in a revised measure of â€˜no evidence of disease activityâ€™ (NEDA-4) in relapsingâ€“remitting multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1297-1305.	3.0	228
113	Placebo controlled trials in neuromyelitis optica are needed and ethical. Multiple Sclerosis and Related Disorders, 2015, 4, 536-545.	2.0	10
114	Reduction of CD8 ⁺ T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e76.	6.0	171
115	Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis. JAMA Neurology, 2015, 72, 897.	9.0	78
116	Simultaneous serum aquaporin-4 antibody and CSF NMDA receptor antibodyâ€“positive encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e101.	6.0	4
117	Fulminant Demyelinating Diseases of the Central Nervous System. Seminars in Neurology, 2015, 35, 656-666.	1.4	17
118	Diagnosing Encephalitis, Not Otherwise Specifiedâ€”Reply. JAMA Neurology, 2015, 72, 726.	9.0	0
119	An ImmunoChip study of multiple sclerosis risk in African Americans. Brain, 2015, 138, 1518-1530.	7.6	60
120	Encephalitis of Unclear Origin Diagnosed by Brain Biopsy. JAMA Neurology, 2015, 72, 66.	9.0	26
121	Challenges and opportunities in designing clinical trials for neuromyelitis optica. Neurology, 2015, 84, 1805-1815.	1.1	39
122	Is TOPIC the last trial for clinically isolated syndrome?. Nature Reviews Neurology, 2015, 11, 6-7.	10.1	1
123	Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. Journal of Neurology, 2015, 262, 326-336.	3.6	20
124	Prognostic biomarkers of IFNb therapy in multiple sclerosis patients. Multiple Sclerosis Journal, 2015, 21, 894-904.	3.0	20
125	Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hocanalyses of the EPOC trial. BMC Neurology, 2014, 14, 220.	1.8	30
126	MS disease activity in RESTORE. Neurology, 2014, 82, 1491-1498.	1.1	166

#	Article	IF	Citations
127	Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e34.	6.0	61
128	Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis: Design of the phase 3 EXPAND trial. Multiple Sclerosis and Related Disorders, 2014, 3, 752.	2.0	13
129	Disease Activity Free Status. JAMA Neurology, 2014, 71, 269.	9.0	132
130	Magnetic Resonance Spectroscopy Markers of Disease Progression in Multiple Sclerosis. JAMA Neurology, 2014, 71, 840.	9.0	57
131	Mycophenolate Mofetil to Treat Neuromyelitis Optica. JAMA Neurology, 2014, 71, 1354.	9.0	4
132	Acute inflammatory myelopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 613-667.	1.8	23
133	2014 Multiple Sclerosis Therapeutic Update. Neurohospitalist, The, 2014, 4, 63-65.	0.8	3
134	Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Annals of Neurology, 2014, 76, 568-580.	5.3	158
135	In vivo evidence of glutamate toxicity in multiple sclerosis. Annals of Neurology, 2014, 76, 269-278.	5.3	88
136	Multiple sclerosis genetics. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 193-209.	1.8	44
137	Precision medicine in chronic disease management: The multiple sclerosis <scp>B</scp>io<scp>S</scp>creen. Annals of Neurology, 2014, 76, 633-642.	5.3	53
138	Genetics of primary progressive multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 211-230.	1.8	17
139	Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurology, The, 2014, 13, 257-267.	10.2	194
140	MOG transmembrane and cytoplasmic domains contain highly stimulatory T-cell epitopes in MS. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e20.	6.0	24
141	Transient hyperckemia in the setting of neuromyelitis optica (NMO). Muscle and Nerve, 2014, 50, 859-862.	2.2	27
142	Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 2013, 70, 248.	9.0	13
143	Patient preferences for attributes of disease modifying Therapies: Results of a choice based conjoint analysis. Value in Health, 2013, 16, A107.	0.3	2
144	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics, 2013, 45, 1353-1360.	21.4	1,213

#	Article	IF	Citations
145	Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls. Human Molecular Genetics, 2013, 22, 4194-4205.	2.9	81
146	Microcystic Inner Nuclear Layer Abnormalities and Neuromyelitis Optica. JAMA Neurology, 2013, 70, 629.	9.0	107
147	Genetic risk variants in African Americans with multiple sclerosis. Neurology, 2013, 81, 219-227.	1.1	54
148	Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 835-843.	3.0	64
149	Acute Transverse Myelitis: Demyelinating, Inflammatory, and Infectious Myelopathies. Seminars in Neurology, 2012, 32, 097-113.	1.4	91
150	Neuromyelitis optica following human papillomavirus vaccination. Neurology, 2012, 79, 285-287.	1.1	47
151	Aquaporin 4â€specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Annals of Neurology, 2012, 72, 53-64.	5.3	281
152	B cell exchange across the blood-brain barrier in multiple sclerosis. Journal of Clinical Investigation, 2012, 122, 4533-4543.	8.2	211
153	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 2011, 476, 214-219.	27.8	2,400
154	Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. Journal of Clinical Neuroscience, 2011, 18, 997-998.	1.5	77
155	Is there a role for planned natalizumab dosage suspension in mitigating progressive multifocal leukoencephalopathy risk?. Neurodegenerative Disease Management, 2011, 1, 11-14.	2.2	0
156	Efficacy of Natalizumab Therapy in Patients of African Descent With Relapsing Multiple Sclerosis. Archives of Neurology, 2011, 68, 464.	4.5	38
157	Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology, 2011, 76, 686-692.	1.1	225
158	Vitamin D in African Americans with multiple sclerosis. Neurology, 2011, 76, 1824-1830.	1.1	67
159	Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy. PLoS ONE, 2011, 6, e16664.	2.5	51
160	DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS OF MULTIPLE SCLEROSIS. CONTINUUM Lifelong Learning in Neurology, 2010, 16, 19-36.	0.8	5
161	Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci. Human Molecular Genetics, 2010, 19, 953-962.	2.9	108
162	Neuromyelitis optica, psychiatric symptoms and primary polydipsia: a case report. General Hospital Psychiatry, 2010, 32, 648.e5-648.e8.	2.4	953

#	Article	IF	Citations
163	Pilot trial of lowâ€dose naltrexone and quality of life in multiple sclerosis. Annals of Neurology, 2010, 68, 145-150.	5.3	90
164	Natalizumab dosage suspension: Are we helping or hurting?. Annals of Neurology, 2010, 68, 395-399.	5.3	108
165	IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci. Genes and Immunity, 2010, 11, 397-405.	4.1	70
166	A Major Histocompatibility Class I Locus Contributes to Multiple Sclerosis Susceptibility Independently from HLA-DRB1*15:01. PLoS ONE, 2010, 5, e11296.	2.5	60
167	Refining the association of MHC with multiple sclerosis in African Americans. Human Molecular Genetics, 2010, 19, 3080-3088.	2.9	35
168	Does race matter for multiple sclerosis?. Neurology, 2010, 74, 532-533.	1.1	10
169	Quantification and Functional Characterization of Antibodies to Native Aquaporin 4 in Neuromyelitis Optica. Archives of Neurology, 2010, 67, 1201-8.	4.5	82
170	Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. Journal of the Neurological Sciences, 2010, 292, 28-35.	0.6	56
171	Genotypeâ€“Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain, 2009, 132, 250-259.	7.6	154
172	Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures. Neurology, 2009, 72, 1760-1765.	1.1	64
173	Distinctive retinal nerve fibre layer and vascular changes in neuromyelitis optica following optic neuritis. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 1002-1005.	1.9	103
174	Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 18680-18685.	7.1	231
175	Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Human Molecular Genetics, 2009, 18, 767-778.	2.9	419
176	Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA. Archives of Neurology, 2009, 66, 226-33.	4.5	92
177	Neuromyelitis optica: Diagnosis, pathogenesis, and treatment. Current Neurology and Neuroscience Reports, 2008, 8, 427-433.	4.2	54
178	F.36. Introduction of a Cell-based Assay Against Native Aquaporin-4-High Specificity and Sensitivity for Neuromyelitis Optica. Clinical Immunology, 2008, 127, S54-S55.	3.2	0
179	Treatment of Neuromyelitis Optica With Rituximab. Archives of Neurology, 2008, 65, 1443.	4.5	445
180	Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology, 2008, 71, 1390-1395.	1.1	119

#	Article	IF	Citations
181	Uncoupling the Roles of HLA-DRB1 and HLA-DRB5 Genes in Multiple Sclerosis. Journal of Immunology, 2008, 181, 5473-5480.	0.8	105
182	Risk Alleles for Multiple Sclerosis Identified by a Genomewide Study. New England Journal of Medicine, 2007, 357, 851-862.	27.0	1,529
183	Identification of new serum autoantibodies in neuromyelitis optica using protein microarrays. Neurology, 2006, 67, 176-177.	1.1	41
184	Emerging Monoclonal Antibody Therapies for Multiple Sclerosis. Neurologist, 2006, 12, 171-178.	0.7	44
185	Multifactor dimensionality reduction reveals geneâ€“gene interactions associated with multiple sclerosis susceptibility in African Americans. Genes and Immunity, 2006, 7, 310-315.	4.1	52
186	Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Human Molecular Genetics, 2006, 15, 2813-2824.	2.9	279
187	Interferon Beta-1a Treatment and African Americansâ€”Reply. Archives of Neurology, 2006, 63, 628.	4.5	0
188	Characterizing the Mechanisms of Progression in Multiple Sclerosis. Archives of Neurology, 2005, 62, 1345.	4.5	105
189	A whole-genome admixture scan finds a candidate locus for multiple sclerosis susceptibility. Nature Genetics, 2005, 37, 1113-1118.	21.4	243
190	An open label study of the effects of rituximab in neuromyelitis optica. Neurology, 2005, 64, 1270-1272.	1.1	607
191	Acute transverse myelitis: Is the "idiopathic" form vanishing?. Neurology, 2005, 65, 1857-1858.	1.1	21
192	Therapeutic Considerations for Disease Progression in Multiple Sclerosis. Archives of Neurology, 2005, 62, 1519-30.	4.5	36
193	Response to Interferon Beta-1a Treatment in African American Multiple Sclerosis Patients. Archives of Neurology, 2005, 62, 1681.	4.5	76
194	Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. Journal of Allergy and Clinical Immunology, 2005, 116, 453-459.	2.9	70
195	Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology, 2004, 63, 2039-2045.	1.1	275
196	Linkage and association with the NOS2A locus on chromosome 17q11 in multiple sclerosis. Annals of Neurology, 2004, 55, 793-800.	5.3	60
197	Mapping Multiple Sclerosis Susceptibility to the HLA-DR Locus in African Americans. American Journal of Human Genetics, 2004, 74, 160-167.	6.2	311
198	Neuromyelitis Optica. Seminars in Neurology, 2002, 22, 105-122.	1.4	128

#	Article	IF	Citations
199	Making Every Step Count: Minute-by-Minute Characterization of Step Counts Augments Remote Activity Monitoring in People With Multiple Sclerosis. Frontiers in Neurology, 0, 13, .	2.4	4